公司資料
Roivant 股價、新聞與催化劑
- 股票代碼:
- ROIV
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
36.30 USD (-1.47%)
收盤價
最後更新: 2026年8月21日
20.3B USD
市值
股價為何變動
As of Aug 21, 2026, ROIV closed down 1.47% at $36.30. No new same-company headline was identified in the current news window.
公司概覽
Vant Operating Model
Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities.
Brepocitinib Autoimmune Franchise
Brepocitinib is an oral JAK1/TYK2 inhibitor under FDA review for dermatomyositis. Priovant is also developing it in late-stage studies for non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris.
IMVT-1402
Immunovant's IMVT-1402 is a fully human anti-FcRn antibody for IgG-mediated autoimmune diseases. Its clinical portfolio spans Graves' disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sjogren's disease and cutaneous lupus erythematosus.
Mosliciguat
Pulmovant is developing mosliciguat, an inhaled soluble guanylate-cyclase activator, for pulmonary hypertension associated with interstitial lung disease.
RNA-Delivery Intellectual Property
Genevant contributes lipid-nanoparticle technology and an associated intellectual-property portfolio for RNA delivery, adding a technology-licensing and patent-enforcement component to Roivant's operating model.
未來催化劑
- Commercial launch of brepocitinib in dermatomyositis by the end of September 2026, subject to FDA approval.
- Topline Phase 3 data for brepocitinib in non-infectious uveitis in the second half of 2026.
- Topline proof-of-concept data for IMVT-1402 in cutaneous lupus erythematosus in the second half of 2026.
- Topline Phase 2 data for mosliciguat in PH-ILD in the second half of 2026.
- Topline data from potentially registrational IMVT-1402 studies in Graves' disease and myasthenia gravis in 2027.
- Topline data from the brepocitinib Phase 3 cutaneous-sarcoidosis study and IMVT-1402 studies in CIDP and Sjogren's disease in 2028.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。